Affinage

CDK13

Cyclin-dependent kinase 13 · UniProt Q14004

Length
1512 aa
Mass
164.9 kDa
Annotated
2026-06-09
54 papers in source corpus 23 papers cited in narrative 23 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CDK13 is a transcriptional cyclin-dependent kinase that pairs with Cyclin K to phosphorylate Ser2 and Ser5 of the RNA polymerase II C-terminal domain, driving transcriptional elongation and processivity (PMID:26748711). Its crystal structure with Cyclin K reveals a C-terminal extension helix bearing a polybasic cluster and a DCHEL motif that contacts bound ATP (PMID:26748711). CDK13 functions largely redundantly with CDK12 in controlling global Pol II elongation: single CDK13 inhibition perturbs growth-signaling transcripts with little effect on viability, whereas dual CDK12/CDK13 inhibition collapses CTD phosphorylation, slows elongation, and triggers widespread alternative 3' polyadenylation and cell death (PMID:32917631). Loss of CDK12/CDK13 activity promotes intronic polyadenylation that truncates DNA damage response genes, producing a BRCAness phenotype, and drives genomic instability through transcription–replication conflicts and stalled replication forks (PMID:31668947, PMID:41882177), a vulnerability that underlies synthetic lethality between CDK12 loss and CDK13 inhibition (PMID:39368479). Beyond elongation, CDK13 shapes RNA processing and splicing through association with RNA processing factors and SR proteins: it interacts with the ASF/SF2-associated protein p32, localizes to nuclear speckles via its N-terminal RS domain, and alters splice-site selection (PMID:25561469, PMID:16721827), and it activates nuclear RNA surveillance by phosphorylating ZC3H14 to promote degradation of aberrant transcripts (PMID:37079685). CDK13 additionally phosphorylates non-transcriptional substrates, including the translation factors 4E-BP1 (Thr46) and eIF4B (Ser422) to control mRNA translation and MYC synthesis (PMID:36882522), the RNA methyltransferases NSUN5 (Ser327) and METTL16 (Ser329) to direct m5C and m6A modifications that stabilize lipogenic mRNAs (PMID:37845385, PMID:41680470), and RBM39 (Ser117) to stabilize RAD50 mRNA and promote DNA repair (PMID:41997449). CDK13 is also exploited by HIV-1, where the Cyclin K/CDK13 complex phosphorylates SERINC5 (Ser360) to enable Nef-mediated antagonism of this antiviral factor (PMID:34380030).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 2006 Medium

    Established CDK13 as a nuclear speckle-associated factor whose RS domain governs localization and whose activity influences constitutive and alternative splicing, framing it as a splicing regulator before its kinase partner was defined.

    Evidence Subcellular fractionation/immunofluorescence, GST pulldown with p32, and in vivo splicing assays

    PMID:16721827

    Open questions at the time
    • Did not identify the catalytic substrate driving splice-site switching
    • Cyclin partner and kinase activity not established here
  2. 2007 Medium

    Identified L-type cyclins as CDK13 binding partners through its kinase domain and showed dose-dependent splicing modulation counteracted by SR proteins, connecting CDK13 to the SR protein splicing machinery.

    Evidence Co-immunoprecipitation, localization imaging, and E1a minigene splicing reporter in HEK293T

    PMID:17261272

    Open questions at the time
    • Direct phosphorylation of SR proteins not demonstrated
    • Functional relevance of Cyclin L versus Cyclin K complexes unresolved
  3. 2008 Medium

    Linked CDK13 to viral mRNA splicing control by showing it binds HIV-1 Tat and shifts viral splicing via ASF/SF2 phosphorylation, suppressing virus production.

    Evidence Reciprocal Co-IP, siRNA knockdown, viral production and splicing assays

    PMID:18480452

    Open questions at the time
    • Direct kinase assay on ASF/SF2 not shown
    • Cyclin dependence of the activity not defined
  4. 2014 Medium

    Placed Cdk13 upstream of Cdk5 in neuronal axon outgrowth, revealing a developmental role distinct from general transcription.

    Evidence siRNA knockdown, in situ hybridization, microarray, and Cdk5 overexpression rescue in P19 and cortical neurons

    PMID:24999027

    Open questions at the time
    • Mechanism by which CDK13 controls Cdk5 expression not defined
    • Direct substrates in neurons not identified
  5. 2015 High

    Defined CDK13 as a bona fide Cyclin K-dependent CTD kinase, providing the structural basis and substrate specificity (Ser2/Ser5 with Ser7 priming) for its transcriptional role.

    Evidence 2.0 A crystal structure of Cdk13/CyclinK and in vitro kinase assays with recombinant proteins

    PMID:26748711

    Open questions at the time
    • In vivo genome-wide CTD targets not mapped in this study
    • Functional distinction from CDK12 not addressed
  6. 2015 High

    Connected CDK13/Cyclin K to RNA processing genome-wide, showing knockdown preferentially impairs snoRNA gene expression and processing through physical association with RNA processing factors.

    Evidence Flag-tag AP-MS, RNA-seq, and siRNA knockdown

    PMID:25561469

    Open questions at the time
    • Direct phosphorylation targets among processing factors not pinpointed
    • Mechanism of snoRNA gene selectivity unknown
  7. 2016 High

    Provided a chemical probe (THZ531) covalently targeting CDK12/CDK13, demonstrating that their inhibition collapses elongating Pol II and downregulates DNA damage response and super-enhancer-driven genes.

    Evidence Co-crystallization, covalent inhibitor design, RNA-seq, Western blot

    PMID:27571479

    Open questions at the time
    • Does not separate CDK13-specific from CDK12-specific transcriptional programs
    • Off-target cysteine reactivity not fully excluded
  8. 2016 Medium

    Revealed an unexpected enrichment of CDK13 in the perinucleolar compartment that excludes its known cyclins and substrates, hinting at a non-canonical structural role.

    Evidence Immunofluorescence, co-localization with PTB, and PNC prevalence quantification

    PMID:26886422

    Open questions at the time
    • Functional significance of PNC localization unresolved
    • Kinase-dependence of PNC enrichment not established
  9. 2019 High

    Showed that CDK12/CDK13 loss induces intronic polyadenylation that truncates DNA damage response transcripts, mechanistically explaining the BRCAness/DNA repair deficiency phenotype.

    Evidence siRNA, SR-4835 inhibitor, RNA-seq, intronic polyadenylation analysis, DNA repair assays

    PMID:31668947

    Open questions at the time
    • CDK13-only contribution versus CDK12 not isolated
    • Direct phosphorylation events controlling IPA not defined
  10. 2020 High

    Used analog-sensitive kinase alleles to establish that CDK13 and CDK12 are substantially redundant for global Pol II processivity, with single CDK13 inhibition affecting growth signaling and dual inhibition being lethal.

    Evidence CRISPR analog-sensitive kinase alleles, RNA-seq, POLII ChIP-seq, viability assays

    PMID:32917631

    Open questions at the time
    • Unique non-redundant CDK13 substrates not catalogued here
    • Basis of partial functional divergence unexplained
  11. 2021 High

    Identified CDK13 as the kinase hijacked by HIV-1 Nef to phosphorylate the restriction factor SERINC5 at Ser360, enabling its surface downregulation and antiviral suppression.

    Evidence AP-MS, in vitro kinase assay with S360A mutagenesis, flow cytometry, infectivity assays

    PMID:34380030

    Open questions at the time
    • Cyclin K dependence of SERINC5 phosphorylation in cells not fully dissected
    • Whether endogenous CDK13 phosphorylates SERINC5 without Nef unknown
  12. 2021 Low

    Reported CDK13 protein interactions (E2F5) and an ADAR1-dependent A-to-I editing event that elevates nucleolar CDK13, tying CDK13 to cancer proliferation, though through weakly reconstituted mechanisms.

    Evidence Co-IP/MS for E2F5; transcriptome sequencing and localization imaging for the c.308A>G editing event

    PMID:33390186 PMID:34496885

    Open questions at the time
    • E2F5 interaction is a single Co-IP/MS without biochemical reconstitution
    • Functional consequence of nucleolar CDK13 redistribution not mechanistically defined
  13. 2023 High

    Identified ZC3H14 as a direct CDK13 substrate whose phosphorylation is necessary and sufficient to activate nuclear RNA surveillance, with patient melanoma mutations abolishing this function.

    Evidence Zebrafish melanoma model, phosphorylation assays, RNA stabilization measurements, sufficiency experiments

    PMID:37079685

    Open questions at the time
    • Phosphosite on ZC3H14 not specified
    • Link between surveillance defect and full oncogenic program incomplete
  14. 2023 High

    Established CDK13 as a direct kinase for translation initiation factors, phosphorylating 4E-BP1 (Thr46) and eIF4B (Ser422) to control mRNA translation and MYC synthesis additively with mTORC1.

    Evidence In vitro kinase assay, site-directed mutagenesis, polysome profiling, pharmacological inhibition

    PMID:36882522

    Open questions at the time
    • In vivo stoichiometry relative to mTORC1 unclear
    • Generality across cell types beyond colorectal cancer untested
  15. 2023 Medium

    Extended CDK13 substrate range to epitranscriptomic and transcriptional regulators, phosphorylating NSUN5 (Ser327) to drive m5C-dependent ACC1 mRNA stability, and selectively repressing PD-L1 transcription distinct from CDK12's IPA-driven role.

    Evidence Co-IP, in vitro kinase assay, m5C profiling, mRNA stability assays (NSUN5); RNAi/overexpression dissection and kinase assay (PD-L1)

    PMID:37164450 PMID:37845385

    Open questions at the time
    • Direct CDK13 contribution to PD-L1 promoter versus elongation not fully separated
    • NSUN5 phosphorylation shown in single lineage
  16. 2023 Medium

    Defined the inhibitor mechanism for CDK12/CDK13 as allosteric destabilization of the Cyclin K interaction rather than simple active-site competition.

    Evidence Lysine reactivity profiling and native mass spectrometry with SR-4835

    PMID:37207290

    Open questions at the time
    • Structural model of the destabilized state not resolved
    • Selectivity between CDK12 and CDK13 not addressed
  17. 2024 Medium

    Demonstrated that CDK13 inactivation drives genomic instability via transcription-replication conflicts and that CDK12-mutant tumors are synthetically lethal with CDK13 inhibition or degradation.

    Evidence CRISPR knockout, organoids, patient-derived xenografts, transcription-replication conflict assays

    PMID:39368479

    Open questions at the time
    • Molecular trigger of the conflicts not pinpointed
    • Resistance mechanisms to CDK13 degraders untested
  18. 2026 Medium

    Further expanded the CDK13 substrate landscape to METTL16 (Ser329) and RBM39 (Ser117), coupling its kinase activity to m6A-driven lipogenic mRNA stability and to RAD50-mediated DNA repair and chemoresistance, and mechanistically linked CDK12/13-dependent elongation to replication fork progression.

    Evidence In vitro kinase assays with mutagenesis, m6A/RNA stability assays, phosphoproteomics, RNAPII pSer2 ChIP-seq, replication fork assays, xenografts

    PMID:41680470 PMID:41882177 PMID:41997449

    Open questions at the time
    • Each substrate validated in a single cancer context
    • Hierarchy among CDK13's many non-transcriptional substrates unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved which CDK13 functions are uniquely non-redundant with CDK12 and how its many direct substrates are prioritized in a given cell.
  • No unified map of CDK13-specific versus CDK12-shared substrates
  • Mechanism coupling transcription elongation to replication fork dynamics incompletely defined
  • No timeline evidence of a CDK13-causative Mendelian disease via direct mutation/rescue

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 7 GO:0016740 transferase activity 3 GO:0140110 transcription regulator activity 3 GO:0140657 ATP-dependent activity 1
Localization
GO:0005730 nucleolus 2 GO:0005654 nucleoplasm 1
Pathway
R-HSA-8953854 Metabolism of RNA 5 R-HSA-73894 DNA Repair 4 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-392499 Metabolism of proteins 1
Partners
CCNKCCNL1CCNL2METTL16NSUN5RBM39SERINC5ZC3H14
Complex memberships
CDK13-Cyclin K

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2015 CDK13 forms a complex with Cyclin K and phosphorylates both Ser2 and Ser5 of the RNA polymerase II CTD, with a preference for substrates bearing Ser7 pre-phosphorylation at a C-terminal position. The crystal structure of Cdk13/CyclinK was determined at 2.0 Å resolution, revealing a C-terminal extension helix with a polybasic cluster and a DCHEL motif that interacts with bound ATP. Crystal structure determination (2.0 Å), in vitro kinase assays with recombinant proteins Cell reports High 26748711
2015 CDK13, isolated as a Flag-tagged complex, associates with numerous RNA processing factors. Knockdown of CDK13 or its cyclin partner CCNK preferentially affects expression of snoRNA genes and leads to defects in RNA processing, and CDK13 physically interacts with RNA processing factors. Flag-tag affinity purification/mass spectrometry, RNA-seq, siRNA knockdown Molecular and cellular biology High 25561469
2007 CDK13 (CDC2L5) interacts with L-type cyclins (Cyclin L1/L2) via its kinase domain; CDK13 and L-type cyclins modulate each other's subcellular localization. Overexpression of CDK13 alters the splicing pattern of E1a minigene reporter transcripts in a dose-dependent manner, and this effect is counteracted by SF2/ASF and SC35. Co-immunoprecipitation, subcellular localization imaging, minigene splicing reporter assay in HEK293T cells Biochemical and biophysical research communications Medium 17261272
2006 CDK13 (CDC2L5) localizes to the nucleoplasm, with enrichment in nuclear speckles dependent on the N-terminal RS domain. CDK13 directly interacts with the ASF/SF2-associated protein p32. Overexpression of CDK13 constructs disturbs constitutive splicing and switches alternative splice site selection in vivo. Subcellular fractionation/immunofluorescence, in vitro GST pulldown, in vivo splicing assays Journal of cellular biochemistry Medium 16721827
2008 CDK13 interacts with HIV-1 Tat both in vivo (co-immunoprecipitation) and in vitro. CDK13 increases HIV-1 mRNA splicing, favors production of the doubly spliced Nef protein, decreases production of viral proteins Gag and Env, and suppresses virus production. CDK13 mediates its effect on splicing through phosphorylation of ASF/SF2. Co-immunoprecipitation, in vitro binding, siRNA knockdown, viral production assays, splicing assays Journal of virology Medium 18480452
2016 THZ531, a covalent inhibitor, irreversibly targets a cysteine residue located outside the kinase domain of CDK12 (and by analogy CDK13, as revealed by co-crystallization with CDK12–Cyclin K). THZ531 causes loss of elongating and hyperphosphorylated RNA Pol II and substantially decreases expression of DNA damage response genes and super-enhancer-associated transcription factor genes. Co-crystallization, covalent inhibitor design, RNA-seq, Western blot Nature chemical biology High 27571479
2020 CDK13 and CDK12 are substantially redundant regulators of global RNA Pol II processivity and transcription elongation. Single inhibition of CDK13 induces transcriptional changes associated with cellular growth signaling pathways with minimal effects on cell viability; dual CDK12/CDK13 inhibition potently induces cell death associated with widespread use of alternative 3′ polyadenylation sites, loss of POLII CTD phosphorylation, and greatly reduced POLII elongation rates. CRISPR-Cas9 analog-sensitive kinase alleles, RNA-seq, POLII ChIP-seq, cell viability assays Science advances High 32917631
2019 Inhibition or loss of CDK12/CDK13 triggers intronic polyadenylation site cleavage that suppresses expression of core DNA damage response proteins, creating a BRCAness phenotype with deficiencies in DNA damage repair. siRNA knockdown, CDK12/13 inhibitor SR-4835, RNA-seq, intronic polyadenylation analysis, DNA damage repair assays Cancer cell High 31668947
2023 CDK13 is required for ZC3H14 phosphorylation, which is necessary and sufficient to promote nuclear RNA degradation. Mutant CDK13 (patient melanoma mutations) fails to activate nuclear RNA surveillance, causing aberrant protein-coding transcripts to be stabilized and translated. Zebrafish melanoma model, phosphorylation assays, RNA stabilization measurements, forced aberrant RNA expression Science (New York, N.Y.) High 37079685
2023 CDK13 directly phosphorylates translation initiation factors 4E-BP1 (at Thr46) and eIF4B (at Ser422). CDK13 inhibition disrupts mRNA translation and reduces MYC oncoprotein synthesis in colorectal cancer cells. CDK13 and mTORC1 have additive effects on 4E-BP1/eIF4B phosphorylation. In vitro kinase assay, site-specific mutagenesis, polysome profiling, pharmacological inhibition, Western blot Oncogene High 36882522
2023 CDK13 interacts with and phosphorylates RNA methyltransferase NSUN5 at Ser327. Phosphorylated NSUN5 catalyzes m5C modification of ACC1 mRNA; the m5C-modified ACC1 mRNA binds ALYREF to enhance mRNA stability and nuclear export, increasing ACC1 expression and lipid deposition in prostate cancer cells. Co-immunoprecipitation, in vitro kinase assay, m5C RNA methylation profiling, mRNA stability assays, gain/loss-of-function studies Cell death and differentiation Medium 37845385
2021 CDK13 interacts with E2F5; this interaction promotes PCa cell proliferation. Transcriptional activation of endogenous CDK13 promotes E2F5 protein expression by facilitating circCDK13 formation (note: the circCDK13-miRNA sponge mechanism is a non-protein product; the CDK13–E2F5 protein interaction is the canonical mechanistic finding here). Co-immunoprecipitation coupled with mass spectrometry, loss-of-function and gain-of-function assays Journal of experimental & clinical cancer research : CR Low 33390186
2021 HIV-1 Nef recruits the Cyclin K/CDK13 complex (identified by affinity purification/mass spectrometry). CycK/CDK13 phosphorylates SERINC5 at Ser360, and this phosphorylation is required for Nef-mediated downregulation of SERINC5 from the cell surface and suppression of its antiviral activity. S360 phosphorylation increases Nef–SERINC5 interaction. Affinity purification/mass spectrometry, in vitro kinase assay, chimeric CD8-SERINC5 constructs, flow cytometry, viral infectivity assays Cell reports High 34380030
2014 Knockdown of Cdk13 in neuronal models (P19 cells and primary cortical neurons) reduces axonal elongation. Cdk13 depletion significantly reduces Cdk5 expression at both mRNA and protein levels. Overexpression of Cdk5 partially rescues the neurite outgrowth defect caused by Cdk13 depletion, placing Cdk13 upstream of Cdk5 in a common signaling pathway. siRNA knockdown, in situ hybridization, Western blot, microarray, Cdk5 overexpression rescue, P19 neuronal differentiation model Experimental neurology Medium 24999027
2016 CDK13 is enriched in the perinucleolar compartment (PNC) throughout the cell cycle, co-localizing with PTB. Neither Cyclin K, Cyclin L (known CDK13 partners), nor CDK13's potential kinase substrates accumulate in PNC. CDK13 overexpression increases PNC prevalence, suggesting CDK13 contributes to PNC formation. Immunofluorescence microscopy, co-localization analysis, PNC prevalence quantification PloS one Medium 26886422
2021 An ADAR1-dependent A-to-I RNA editing event in the CDK13 coding region (c.308A>G) promotes cancer cell hallmarks (viability, proliferation, invasion). This editing event increases the nucleolar abundance of CDK13 protein and may explain ADAR1-dependent global splicing changes. Whole transcriptome sequencing, RNA editing validation, functional cell assays, subnuclear localization microscopy, gene silencing Molecular cancer Medium 34496885
2023 CDK13 inhibition by AR-A014418 represses transcription of PD-L1. CDK12 inhibition by the same compound enhances intronic polyadenylation (IPA) of PD-L1, generating a secreted isoform. Dual CDK12/CDK13 inhibition dramatically suppresses full-length PD-L1. These roles were confirmed by RNA interference and protein overexpression of CDK12 and CDK13 individually. In vitro kinase assay with recombinant proteins, RNA interference, protein overexpression, qRT-PCR, Western blot, flow cytometry Journal for immunotherapy of cancer Medium 37164450
2024 CDK13 inactivation drives genomic instability via transcription-replication conflicts. CDK12-mutant organoids and patient-derived xenografts are sensitive to CDK13 inhibition or degradation, establishing synthetic lethality between CDK12 loss and CDK13 inhibition. CRISPR knockout, organoid models, patient-derived xenografts, CDK13 inhibitor/degrader treatment, transcription-replication conflict assays Cell reports. Medicine Medium 39368479
2023 The inhibitor SR-4835 binding to CDK12/CDK13 greatly destabilizes their interaction with Cyclin K in an allosteric manner (not simply active-site competition), as revealed by lysine reactivity profiling and native mass spectrometry. Structural mass spectrometry (lysine reactivity profiling + native MS) Journal of the American Chemical Society Medium 37207290
2026 CDK13 directly phosphorylates METTL16 at Ser329, augmenting its catalytic activity to install m6A modifications on ACLY mRNA. These m6A marks are recognized by YTHDC2, stabilizing ACLY mRNA and increasing acetyl-CoA production to fuel lipogenesis in clear cell renal cell carcinoma. In vitro kinase assay, m6A profiling, mRNA stability assays, gain/loss-of-function, in vivo xenograft models Experimental & molecular medicine Medium 41680470
2026 CDK13 directly phosphorylates RBM39 at Ser117. This phosphorylation enhances RBM39 binding to and stabilization of RAD50 mRNA, increasing RAD50 protein levels and promoting DNA damage repair, thereby conferring cisplatin resistance in endometrial cancer. Phosphoproteomic analysis, in vitro kinase assay, RNA binding/stability assays, loss-of-function studies, in vivo xenograft models The Journal of biological chemistry Medium 41997449
2023 Cyclin O (CCNO) interacts with CDK13 (by co-immunoprecipitation) and promotes proliferation signaling activation in lung adenocarcinoma; a CDK13 inhibitor abrogates the oncological effect of CCNO overexpression. Co-immunoprecipitation, Western blot, CDK13 inhibitor treatment, xenograft model Journal of thoracic disease Low 37197505
2026 CDK12/CDK13 inhibition in glioblastoma stem cells (GSCs) causes rapid, genome-wide loss of RNAPII CTD Ser2 phosphorylation, abolishing transcriptional elongation. Unexpectedly, CDK12/CDK13 inhibition also arrests DNA replication fork progression, preceding DNA damage response activation, directly linking RNAPII elongation to replication fork dynamics. CDK12/13 inhibitor treatment, RNAPII pSer2 ChIP-seq, DNA replication fork assays, RNA-seq, xenograft models EMBO molecular medicine Medium 41882177

Source papers

Stage 0 corpus · 54 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2016 Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nature chemical biology 283 27571479
2019 Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer cell 239 31668947
2015 Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in C-terminal domain phosphorylation, gene transcription, and RNA processing. Molecular and cellular biology 165 25561469
2020 CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. Science advances 133 32917631
2015 Structural and Functional Analysis of the Cdk13/Cyclin K Complex. Cell reports 127 26748711
2012 Cyclin K goes with Cdk12 and Cdk13. Cell division 95 22512864
2018 Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium. Transcription 84 30319007
2012 Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PloS one 81 22912832
2023 CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA. Cell death and differentiation 72 37845385
2022 Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13. Journal of medicinal chemistry 57 35938508
2007 CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing. Biochemical and biophysical research communications 56 17261272
2006 CDC2L5, a Cdk-like kinase with RS domain, interacts with the ASF/SF2-associated protein p32 and affects splicing in vivo. Journal of cellular biochemistry 53 16721827
1998 Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3. Genomics 51 9740677
2021 CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis. Journal of experimental & clinical cancer research : CR 48 33390186
2008 CDK13, a new potential human immunodeficiency virus type 1 inhibitory factor regulating viral mRNA splicing. Journal of virology 48 18480452
2021 An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks. Molecular cancer 47 34496885
1999 Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma. Cancer genetics and cytogenetics 47 9973934
2023 Oncogenic CDK13 mutations impede nuclear RNA surveillance. Science (New York, N.Y.) 42 37079685
2017 Phenotypic and molecular characterisation of CDK13-related congenital heart defects, dysmorphic facial features and intellectual developmental disorders. Genome medicine 40 28807008
2023 Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids. Journal of experimental & clinical cancer research : CR 38 37202753
2017 Heterozygous mutations affecting the protein kinase domain of CDK13 cause a syndromic form of developmental delay and intellectual disability. Journal of medical genetics 36 29021403
2022 Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer. Cancer research 34 35857807
2024 CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell reports. Medicine 29 39368479
2014 Cdk12 and Cdk13 regulate axonal elongation through a common signaling pathway that modulates Cdk5 expression. Experimental neurology 28 24999027
2018 De novo variants in CDK13 associated with syndromic ID/DD: Molecular and clinical delineation of 15 individuals and a further review. Clinical genetics 21 29393965
2018 CDK13-related disorder. Advances in genetics 21 30904094
2019 Insight into the molecular mechanism of LINC00152/miR-215/CDK13 axis in hepatocellular carcinoma progression. Journal of cellular biochemistry 20 31297882
2016 CDK13, a Kinase Involved in Pre-mRNA Splicing, Is a Component of the Perinucleolar Compartment. PloS one 19 26886422
2007 Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice. Carcinogenesis 19 17389615
2023 CDK13 phosphorylates the translation machinery and promotes tumorigenic protein synthesis. Oncogene 17 36882522
2022 CDK13-related disorder: Report of a series of 18 previously unpublished individuals and description of an epigenetic signature. Genetics in medicine : official journal of the American College of Medical Genetics 16 35063350
2019 Mouse Model of Congenital Heart Defects, Dysmorphic Facial Features and Intellectual Developmental Disorders as a Result of Non-functional CDK13. Frontiers in cell and developmental biology 16 31440507
2021 HIV-1 Nef interacts with the cyclin K/CDK13 complex to antagonize SERINC5 for optimal viral infectivity. Cell reports 14 34380030
2021 CDK13-Mediated Cell Cycle Disorder Promotes Tumorigenesis of High HMGA2 Expression Gastric Cancer. Frontiers in molecular biosciences 14 34513922
2017 Redefining the phenotypic spectrum of de novo heterozygous CDK13 variants: Three patients without cardiac defects. European journal of medical genetics 13 29222009
2023 MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma. Journal of experimental & clinical cancer research : CR 11 37599362
2019 One-month-old girl presenting with pseudohypoaldosteronism leading to the diagnosis of CDK13-related disorder: a case report and review of the literature. Journal of medical case reports 9 31883531
2023 Structural Mass Spectrometry Probes the Inhibitor-Induced Allosteric Activation of CDK12/CDK13-Cyclin K Dissociation. Journal of the American Chemical Society 8 37207290
2023 AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells. Journal for immunotherapy of cancer 7 37164450
2022 The utility of DNA methylation signatures in directing genome sequencing workflow: Kabuki syndrome and CDK13-related disorder. American journal of medical genetics. Part A 7 35043535
2024 Physiological and pathological roles of the transcriptional kinases CDK12 and CDK13 in the central nervous system. Cell death and differentiation 5 39533070
2021 Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13. Journal of human genetics 5 33879837
2023 A Prenatal Presentation of CDK13-Related Disorder with a Novel Pathogenic Variant. Case reports in genetics 4 37351084
2025 CDK13-Related Disorder: Novel Insights From A Series of 27 Cases and Recommendations for Clinical Management. Clinical genetics 3 39971730
2024 Methionine restriction promotes cisplatin sensitivity of gastric cancer resistant cells by down-regulating circ-CDK13 level. Experimental cell research 3 39488295
2026 CDK13 drives clear cell renal carcinoma through METTL16-mediated m6A modification of ACLY mRNA. Experimental & molecular medicine 2 41680470
2024 ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner. BMC biology 2 38835016
2023 Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction. Journal of thoracic disease 2 37197505
2026 CDK12 and CDK13 in oncology: from RNA regulation to therapeutic targeting. Cellular oncology (Dordrecht, Netherlands) 0 41491919
2026 Roles of CDK12/CDK13 and development of inhibitors and degraders. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 0 41687544
2026 CDK12/CDK13 inhibition disrupts transcriptional elongation and replication fork progression in glioblastoma. EMBO molecular medicine 0 41882177
2026 Phosphorylation of RBM39 by CDK13 stabilizes RAD50 mRNA to drive cisplatin resistance in endometrial cancer. The Journal of biological chemistry 0 41997449
2025 Validation of a hypomorphic variant in CDK13 as the cause of CHDFIDD with autosomal recessive inheritance through determination of an episignature. Clinical epigenetics 0 39800774
2023 Deciphering congenital heart defects, facial dysmorphism and intellectual developmental disorder (CHDFIDD) associated with constitutional CDK13 pathogenic variants - case report and literature review. Annals of agricultural and environmental medicine : AAEM 0 38549490

Missed literature

Know a paper Affinage missed for CDK13? Flag it for the maintainers and the community.

No submissions yet.